Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2010

View Archived Issues

GO-CoA-Tat controls glucose and weight in preclinical study

Merck & Co. identifies novel glucocorticoid receptor modulators

Asymmetrical CADA analogue VGD-020 displays improved potency against CD4

In vitro data support potential benefits of TT-30 in complement-mediated diseases

New CREB-1 inhibitor XX-650-23 shows promise to treat AML

Pfizer identifies new GPR119 agonists

New antagonists of protease-activated PAR1 receptor claimed

Leo Pharma claims new positive modulators of calcium-sensing CaS receptor

Vertex Pharma patents new inhibitors of hepatocyte growth factor receptor

Gel formulation of IQP-0528 plus tenofovir evaluated in vitro as HIV therapy

Pro-Pharmaceuticals and Mount Sinai School of Medicine to evaluate galectin-targeting agents

King Pharmaceuticals resubmits Remoxy NDA to FDA

Degludec improves long-term glycemic control in phase IIIa diabetes trials

Exiqon offers services for microRNA biomarker screening and diagnostic assay development

AVI BioPharma advances Duchenne's muscular dystrophy program

Transition Therapeutics and Elan modify ELND-005 collaboration agreement

Cephalon discontinues development of Nuvigil for jet lag

FDA reports on ongoing safety review of somatropin

European release of Xpert Flu test for influenza A, B and 2009 H1N1 strain

Vicus begins phase II trial of VT-122 in advanced HCC

Repros completes preclinical studies of vaginal Proellex formulation

European sale of Ruconest begins in Denmark and Norway

EMA to review Allos' MAA for Folotyn in relapsed or refractory PTCL

Emergent BioSolutions begins phase I trial of anthrax vaccine NuThrax

Intellect Neurosciences reports phase Ib data on Alzeimer's disease candidate OX1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...